DermTech's Non-Invasive Pigmented Lesion Assay to Detect and Track Lesions for Suspected Melanoma and to Determine Outcomes for up to 2 Years

Melanoma Detection Clinical Trial

— TRUST  

Official title:

Clinical Practice Utility Study to Assess DermTech's Non-Invasive Pigmented Lesion Assay to Detect and Track Lesions for Suspected Melanoma and to Determine Outcomes for up to 2 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04563949
• Other study ID #: 17-02
• Status: Completed
• Start date: November 16, 2017
• Est. completion date: December 15, 2020

Study information

• Verified date: September 2020
• Source: DermTech
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multi-center, sample collection study to follow clinically suspicious lesions to determine the outcome including surgical biopsy, removal, monitoring, etc. for up to 2 years after lesion identification. Subjects who had, or will have a DermTech Pigmented Lesion Assay completed on a lesion suspected of being melanoma are eligible for the study. Based on historical data, an expected melanoma rate of approximately 5% to 10% is anticipated.

Description:

This is a multi-center, sample collection study to follow clinically suspicious lesions to determine the outcome including surgical biopsy, removal, monitoring, etc. for up to 2 years after lesion identification.

Subjects will be consented and enter the trial to have their suspicious lesion(s), biopsied via DermTech's adhesive patch biopsy and assessed with DermTech's non-invasive PLA, and followed up to 2 years per standard of care. Lesions must be photographed and/or the site of the lesion anatomically defined to permit follow-up of the lesion(s) and lesional site(s) during future visits.

Subjects will be followed per standard of care for lesion biopsy, excision, treatment and/or monitoring. Other than DermTech's non-invasive PLA of the lesion(s) no other study procedures will be performed and subjects will be treated according to the standard of care. The subject's medical management team should use standard of care, visual assessment changes (i.e., "ABCDE") and physician judgment for suspicious lesion characterization and monitoring when planning the subject's course of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 323
• Est. completion date: December 15, 2020
• Est. primary completion date: November 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Males and females the treating physician chose to use the PLA on;

2. Presence of a lesion(s) that is suspicious for melanoma and a candidate for surgical biopsy that was previously biopsied with DermTech's adhesive patch biopsy and assessed via PLA;

3. Willing to permit subsequent PLA assays to be performed on suspicious lesions;

4. Willing to follow standard of care treatment for the lesion(s) as determined by the treating physician;

5. Subjects must be able to complete study visits required by the protocol (subject is not planning to relocate or travel thus prevent attendance at future study visits; and

6. Willing to provide informed consent to participate in this trial.

Exclusion Criteria:

1. Has confirmed melanoma or a suspicious lesion that required a surgical biopsy or excision prior to the intial PLA on that lesion of interest;

2. Has an ulcerated or bleeding lesion that could cofound the PLA results;

3. Has a suspicious lesion(s) in an area that was previously surgically biopsied;

4. The lesion(s) is on the palms, mucosal surface, or other area where adhesive patch biopsies cannot be performed;

5. Has an allergy to tape or latex rubber;

6. Receipt of any investigational drug therapy within four weeks of study enrollment, or concurrent participation in another interventional clinical study deemed by the treating physician to potentially influence this study; and

7. Documented substance abuse, any other significant medical condition or laboratory result that would indicate an unreasonable risk to the subject or potential interference with study procedures, or would negatively affect the patient's reliability and compliance with the study schedule of events. -

Related Conditions & MeSH terms

• Melanoma
• Melanoma Detection

Intervention

Other:
• Repeat Testing
Repeat Testing with the PLA will be conducted

Locations

Country	Name	City	State
United States	West Dermatology	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
DermTech

Country where clinical trial is conducted

United States, 

References & Publications (2)

Ferris LK, Jansen B, Ho J, Busam KJ, Gross K, Hansen DD, Alsobrook JP 2nd, Yao Z, Peck GL, Gerami P. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. JAMA Dermatol. 2017 Jul 1;153(7):675-680. doi: 10.1001/jamadermatol.2017.0473. — View Citation

Gerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2. doi: 10.1016/j.jaad.2016.07.038. Epub 2016 Oct 1. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects without surgical biopsy	The proportion of subjects who exit the study without surgical biopsy out to approximately up to 24 months ± SOC	approximately up to 24 months
Secondary	Results of PLA results compared to biopsy	Expression of genes during the 2-year study. The association of gene expression and algorithm values with melanoma versus non-melanoma will be examined using clinical performance indicators negative predictive value with their respective 95th percentile confidence intervals.	approximately up to 24 months